JNJ
The tariff tab
Johnson & Johnson just put a rough price tag on trade drama: about $400 million in expected 2025 pain from tariffs. Most of that hit should land in medtech, where costs can sneak through the door like an uninvited guest and then show up later in the profit-and-loss statement.
Still standing, but with a flinch
The good news for shareholders? J&J says it still expects to top full-year revenue guidance and meet its earnings forecast even after accounting for the tariffs currently in place. That’s a pretty classic corporate message: yes, this is annoying; no, we’re not panicking.
CFO Joe Walk said the impact is likely to be felt as inventory costs first, then bleed into future periods. Translation: the bill isn’t disappearing — it’s just taking the scenic route through the balance sheet.
The bigger worry
What has management more concerned is the possibility of tariffs on pharmaceuticals themselves. Those are still exempt for now, but if Washington changes course, Duato warned it could create supply-chain headaches and even shortages. That’s a lot more serious than a margin headache; investors hate shortages because shortages can hit sales, reputation, and planning all at once.
Why you should care
J&J is one of the market’s boring-in-a-good-way giants, which means investors usually like the predictability. Tariffs turn that into a little less predictable, especially if the policy spreads beyond steel, aluminum, and China-related levies.
Big picture: J&J is still saying the engine is humming, but tariffs are now the pothole in the road — and the company is bracing for a few bumps before the year is over.